The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. Two recent phase 1 studies of anti-PD-1 antibodies indicate that these agents exhibit considerable antitumor activity alone or in combination with ipilimumab in patients with advanced melanoma.
*Click on the links to the left for PDFs of the full article and related Commentary.